elbion Merges With 4AZA to Form European Drug Discovery and Development Company


elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered at 4AZA's current site in Leuven, where it will concentrate its corporate functions, business development activities and its research facilities for immunology. elbion AG's facilities and staff in Radebeul will be retained and continue to drive the largest part of the company's fully integrated drug discovery and development activity.

Bernd Kastler, CEO of elbion AG will be CEO of the combined group and will re-locate to Leuven and be joined by Thomas Taapken as CFO and Thomas Kronbach as CSO. Mark de Boer, former CEO of 4AZA will remain with elbion as a consultant to the company.

elbion's board includes Ann F. Hanham (Burrill & Company), Alexander Asam (Deutsche Venture Capital), Stephen Evans-Freke (independent board member), Luc Philips (independent board member), Staf Van Reet (independent board member), Christoph Schröder (TVM Capital), Klaus Stöckemann (3i), Claude Stoufs (Capricorn) and Bernd Kastler who acts as interim Chairman.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances